ALK receives positive recommendation for EURneffy 1 mg: A needle-free anaphylaxis treatment for children
Inside Information ALK (ALKB:DC / OMX: ALK B) today announced that the…
Skyhawk Therapeutics Announces Nine Month Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease
Nine-month findings show mean improvement in Composite Unified Huntington's Disease Rating Scale…
Real-World Commercial Experience with Ryoncil Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment
January 26, 2026 18:45 ET | Source: Mesoblast Limited NEW YORK, Jan.…
FDA Accepts LEQEMBI IQLIK (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimers Disease under Priority Review
If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment…
Ark Biopharmaceutical Receives China Marketing Authorization for Aizhida for the Treatment of ADHD
SHANGHAI, Jan. 8, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio")…
Ark Biopharmaceutical Receives China Marketing Authorization for Azstarys for the Treatment of ADHD
SHANGHAI, Jan. 6, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio")…
Relapse Risk Increases During the Holidays; Desert Hope Treatment Center Urges Early Support
LAS VEGAS, Dec. 24, 2025 (GLOBE NEWSWIRE) -- This holiday season, addiction…
U.S. FDA Approves Agios AQVESME (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia
AQVESME is the only FDA-approved medicine for anemia in both non-transfusion-dependent and…
Menarini Silicon Biosystems announces PACE trial biomarker analysis results confirming clinical utility of CELLSEARCH CTC enumeration to guide treatment decisions in a specific metastatic breast cancer subtype
The secondary analysis of the PACE trial highlights the value of counting…
Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD
December 11, 2025 18:22 ET | Source: Mesoblast Limited NEW YORK, Dec.…
